Foresite Capital — Full Portfolio

Fulcrum Therapeutics develops small-molecule drugs targeting rare genetic diseases with significant unmet treatment needs, with its lead candidate pociredir in clinical testing for sickle cell disease as an oral therapy designed to increase fetal hemoglobin levels.

BiotechCambridge, US

Robert Gould(Executive Officer, Director)inACAlex C. Sapir(President and Chief Executive Officer, Director)in

BoardAEAlan Ezekowitz(Director)inMLMark Levin(Director)inJames Geraghty(Director)James Collins(Director)

Board seatJames Tananbaum· per SEC Form D

Co-investorsTHThird Rock Ventures

10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers.

BiotechDeep TechHardwareHealthtechPleasanton, US

SSSerge Saxonov(Founder)inBHBen Hindson(Founder)inBrad Crutchfield(Chief Commercial Officer)JPJean Philibert(Chief People Officer)Eric S Whitaker(General Counsel)inJustin McAnear(Chief Financial Officer)

Co-investorsFOFoothill VenturesKHKhosla VenturesOMOMX VenturesPAPaladin Capital GroupSOSoftBank Vision FundVEVenrock+4 more

Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.

BiotechHealthtechMedical DevicesWayne, US

Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)SDStuart D. Shanler(Executive Officer)inJoseph Monahan(Executive Officer)inHDHugh Davis(Executive Officer, Director)inJames Loerop(Executive Officer)

Co-investorsAIAisling CapitalAPAPERTURE Venture PartnersF-F-Prime CapitalRARA CapitalSOSofinnova VenturesSOSofinnova Venture Partners+1 more

Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles.

BiotechWaltham, US

Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHGHalley Gilbert(Executive Officer)RDRebecca Dabora(Executive Officer)inEllie Hershberger(Executive Officer)

Co-investorsFIFidelity InvestmentsGVGV (Google Ventures)MIMITHRILMIMithril Capital ManagementOROrbiMedPOPolaris Partners+3 more

Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.

BiotechHealthtechMedical DevicesAbingdon, Oxfordshire, US

James Noble(Chief Executive Officer)ARAdrian Rawcliffe(Chief Executive Officer and Director)inGWGavin Wood(Chief Financial Officer)inWBWilliam Bertrand(Chief Operating Officer)inJLJohn Lunger(Chief Patient Supply Officer)inENElliot Norry(Chief Medical Officer)in

Co-investorsAVAvoro Capital AdvisorsEIEight Roads VenturesF-F-Prime CapitalNENew Enterprise Associates (NEA)RIRidgeback Capital

Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSeattle, US

CRChad Robins(Executive Officer, Director)inHRHarlan Robins(Executive Officer)inKDKathleen Determann(Executive Officer)inDean Schorno(Executive Officer)inChris Carlson(Executive Officer)KPKyle Piskel(Chief Financial Officer)in

Co-investorsDEDecheng CapitalFMFMG CapitalKHKhosla VenturesOROrbiMed

Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.

BiotechHealthtechMenlo Park, US

Aya Jakobovits(Executive Officer, Director)NHNathan Hubbard(Executive Officer)inChen Schor(President, Chief Executive Officer and Director)in

BoardJSJonathan Silverstein(Director)inCGCarl Gordon(Director)inFlorent Gros(Director)

Co-investorsOROrbiMedPOPontifax Venture CapitalQUQuan CapitalAMaMoonNONovartis Venture FundPUPureTech Health

Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.

AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US

ARArnon Rosenthal(Ph.D.)inTGTillman Gerngross(Director)ARArnon Rosenthal PhD(Founder)in

BoardCarl Gordon(Director)TMTerry McGuire(Director)in

Co-investorsMIMission Bay CapitalMIMission BiocapitalMRMRL Ventures FundSVSV Health InvestorsPOPolaris Partners

Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.

BiotechHealthtechMedical DevicesSouth San Francisco, US

ROBERT ABRAHAM(Director)JAJOSHUA A. KAZAM(Executive Officer, Director)DMDAVID M. TANEN(Executive Officer)FRANZ HUMER(Director)JOHN DEYOUNG(Director)

BoardOWOWEN WITTE(Director)

Co-investorsAVAvoro Capital AdvisorsTPTPGVIVida VenturesGIGilead SciencesVVVVAG Special

ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.

BiotechHealthtechMedical Devices

CGCorey Goodman(Chairman)inJLJason Lettmann(Chief Executive Officer)in

Co-investorsLILightstone VenturesAGage1VEvenBio PartnersLOLogosVIVivo Capital

Arbutus is a biotechnology company developing therapeutic assets and bringing them to market, with expertise spanning scientific, clinical, operational, and financial development.

BiotechHealthtechWarminster, US

WHWilliam H. Collier(President and Chief Executive Officer)inGaston Picchio(Chief Development Officer)inMichael J. McElhaugh(Chief Business Officer)inDCDavid C. Hastings(Chief Financial Officer)inMJMichael J. Sofia(Chief Scientific Officer)inElizabeth Howard(Executive Officer)in

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)EDElisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)

Co-investorsADAdvent Life SciencesCHChiesi VenturesDRDroia VenturesJAJazzya InvestmentsMEMedicxiMYMyelin VC+4 more

Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.

BiotechDeep TechMedical DevicesCambridge, US

DRDavid R. Liu(Founder and Inventor)inJKJ. Keith Joung(Founder and Inventor)inFZFeng Zhang(Founder and Inventor)DRDavid R. Liu, Ph.D.(Founder and Inventor)JKJ. Keith Joung, M.D., Ph.D.(Founder and Inventor)FZFeng Zhang, Ph.D.(Founder and Inventor)

Co-investorsARARCH Venture PartnersDRDreamers VCEIEight Roads VenturesF-F-Prime CapitalGVGV (Google Ventures)HOHongShan Capital Group+1 more

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors.

Ivan Hyep(Chief Financial Officer and Treasurer)inLara Meisner(Chief Legal Officer, Compliance Officer and Corporate Secretary)inDRDavid Raben(Chief Medical Officer)in

Co-investorsAIAisling CapitalEIEight Roads VenturesF-F-Prime CapitalPRPremji InvestRARA CapitalRERed Tree Venture+5 more

CASI Pharmaceuticals is a biopharmaceutical company developing CID-103, an investigational anti-CD38 monoclonal antibody targeting B memory, plasmablasts, and plasma cells.

BiotechHealthtechBeijing

CWChunhua Wang(Chief Operating Officer)WGWei Gao(General Counsel)HHHai Huang(Global Chief Commercial Officer)Alexander A. Zukiwski(Chief Medical Officer)Wei (Larry) Zhang(President)Wei-Wu He(Chief Executive Officer, Chairman of the Board of Directors)

Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation.

BiotechHealthtechHampton, US

Anthony S. Marucci(Executive Officer, Director)inAvery W. Catlin(Executive Officer)

BoardRichard van den Broek(Director)Timothy M. Shannon, M. D.(Director)Herbert J. Conrad(Director)Karen Shoos(Director)

CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.

BiotechHealthtechMedical Devices

AKArthur Kuan(Chairman and Chief Executive Officer)in

Co-investorsDEDecheng CapitalLOLongitude CapitalPAPalm Drive CapitalRARA CapitalTCTCG CrossoverACACORN BIOVENTURES+2 more

Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations.

BiotechHealthtechCambridge, US

STSchuetz Thomas(Executive Officer, Director)inEAErrik Anderson(Executive Officer, Director)inTJThomas J. Schuetz(Executive Officer, Director)inVered Bisker-Leib(Executive Officer)inBarry Shin(Chief Financial Officer)inNLNeil Lerner(Senior Vice President, Chief Accounting Officer)in

Co-investorsBIBioBritF-F-Prime CapitalOROrbiMedVEvenBio PartnersVIVivo Capital

Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.

BiotechSan Diego, US

Richard Scott Struthers(Executive Officer, Director)SFStephen F. Betz(Executive Officer)inSBStephen Betz(Chief Scientific Officer)inRSR. Scott Struthers(President, Chief Executive Officer and Director)inTSTobin Schilke(Chief Financial Officer)inIKIsabel Kalofonos(Chief Commercial Officer)in

Co-investors5A5AM VenturesOROrbiMedRARA CapitalVIVivo Capital

Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation.

BiotechHealthtechMedical Devices

MKMary Kay Fenton(Chief Financial Officer)inJeffrey Jones(Chief Medical Officer)JMJennifer Michaelson(Chief Scientific Officer)inCorinne Savill(Chief Business Officer)inJacquelyn Sumer(Chief Legal and Compliance Officer and Secretary)inNANadim Ahmed(President and Chief Executive Officer)in

Co-investorsNENextech InvestBIBiotechnology Value FundOROrbiMed

Cytokinetics develops potential medicines for cardiovascular and neuromuscular diseases characterized by impaired muscle function.

BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US

James SpudichinRonald ValeLawrence S.B. GoldsteinRIRobert I. Blum(President and Chief Executive Officer)in

BoardJames Sabry

Denali Therapeutics develops therapeutics for neurodegenerative diseases.

BiotechHealthtechMedical DevicesSan Francisco, US

MTMarc Tessier-Lavigne(Director)inRyan Watts(Executive Officer, Director)inAOAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSESteve E. Krognes(Director)in

Co-investorsARARCH Venture PartnersECEcoR1 CapitalF-F-Prime CapitalARARCH VentureFLFlagship VenturesGVGV (Google Ventures)

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

JQJohn Quisel(Chief Executive Officer)inJFJean Franchi(Chief Financial Officer)inJYJonathan Yu(Chief Operating Officer)inWSWill Savage(Chief Medical Officer)inPSPamela Stephenson(Chief Commercial Officer)inSCSteve Caffé(Chief Regulatory Officer)in

Co-investorsACAccess BiotechnologyATAtlas VentureBABain Capital Life SciencesFRFrazier Life SciencesOROrbiMed5A5AM Ventures+6 more

Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.

BiotechDigital HealthBoulder, US

Kevin Koch(Executive Officer, Director)inARAlan Russell(Director)inBEBadreddin Edris(Director and Co-Founder)inKenneth Harrison(Director)

BoardPTPeter Thompson(Director)inJRJonathan Root(Director)in

Co-investorsBOBoulder VenturesOROrbiMedUSUS Venture PartnersDEDeerfield Management CompanyNONovo Holdings

A pharmaceutical company whose executive team emphasizes innovation and patient care.

BiotechDigital HealthMental Health

Co-investorsRARA Capital

GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Jeffrey T. Huber(Director)JOJoshua Ofman, MD, MSHS(Chief Executive Officer)inAFAaron Freidin(Executive Officer)inJOJosh Ofman(Executive Officer)inRobert Ragusa(Executive Officer, Director)JCJennifer Cook(Executive Officer, Director)in

Co-investorsAMAmino CapitalARARCH Venture PartnersBEBezos ExpeditionsBLBluebird VenturesDEDecheng CapitalDEDentsu Ventures+8 more

Hinge Health builds a digital healthcare platform designed to help individuals manage musculoskeletal health and related conditions.

Digital HealthHealthtechMedical DevicesWellness & FitnessSan Francisco, US

GMGabriel Mecklenburg(Executive Officer, Director)inDPDaniel Perez(Executive Officer, Director)in

Co-investors1111.2 CapitalALAlkeon InnovationBEBessemer Venture PartnersCACannage CapitalCOCoatue ManagementDUDuke Capital Partners+9 more

Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.

BiotechDigital HealthHealthtechMedical Devices

WLWill Lewis(Chair and Chief Executive Officer)inGeoffrey AllaninSBSara Bonstein(Chief Financial Officer)inRARoger Adsett(Chief Operating Officer)MFMartina Flammer(Chief Medical Officer)inSNS. Nicole Schaeffer(Chief People Strategy Officer)in

Co-investorsBEBessemer Venture PartnersF-F-Prime CapitalOROrbiMedPRProspect Venture PartnersNVNVIDIA

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

NBNessan Bermingham(Executive Officer, Director)inJennifer Doudna(Co-founder)JRJose Rivera(Executive Officer)inJLJohn Leonard(President and Chief Executive Officer)inJBJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEDEdward Dulac(Executive Vice President, Chief Financial Officer)in

Co-investorsAGage1ATAtlas VentureAVAvoro Capital AdvisorsECEcoR1 CapitalFIFidelity InvestmentsOROrbiMed

Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.

BiotechHealthtech

MEMarc Elia(Founder)in

Co-investorsBABain Capital Life SciencesMRMRL Ventures FundPRPremji InvestGVGV (Google Ventures)MIMITHRILMIMithril Capital Management+3 more

Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart.

BiotechHealthtechLexington, US

Jasbir S. Seehra(Executive Officer, Director)inJasbir Seehra(Co-Founder, Chief Executive Officer and Director)in

BoardJulius Knowles(Director)ALAlon Lazarus(Director)inOhad Hammer(Director)Ran Nussbaum(Director)in

Co-investorsARArkin CapitalOROrbiMedPOPontifax Venture Capital

Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

BiotechDigital HealthMedical DevicesLa Jolla, US

TWTROY WILSON(Executive Officer, Director)inPINGDA REN(Executive Officer)inYLYI LIU(Executive Officer)inTWTroy Wilson(Founder)inTETroy E. Wilson(President and Chief Executive Officer, Chairman of the Board)inHEIDI HENSON(Executive Officer)in

Co-investorsARARCH Venture PartnersAVAvoro Capital AdvisorsECEcoR1 CapitalNENextech InvestOUOUP (Osage University Partners)ARARCH Venture

Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for metabolic-associated steatohepatitis (MASH).

BiotechHealthtechMedical DevicesConshohocken, US

RTRebecca Taub(Founder and Director)inMRMarc R. Schneebaum(Executive Officer)inPaul A. Friedman(Executive Officer, Director)inBSBill Sibold(President and Chief Executive Officer)inMardi Dier(Executive Vice President and Chief Financial Officer)inCHCarole Huntsman(Executive Vice President and Chief Commercial Officer)in

Co-investorsAVAvoro Capital AdvisorsBABay City Capital

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

CHCharles Homcy(Director)JCJason Coloma(Chief Executive Officer)in

Co-investorsANAndreessen HorowitzARARCH Venture PartnersFRFrazier Life SciencesGVGV (Google Ventures)JAJanus Henderson InvestorsTHThird Rock Ventures+1 more

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.

BiotechDigital HealthHealthtechMedical Devices

MRMatthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)inSteven Chapman(Chief Executive Officer & President)

Co-investorsBABain Capital Life SciencesCHCheyenne VenturesCLClaremont Creek VenturesHAHarmony PartnersLILightspeed Venture PartnersRARA Capital+2 more

Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.

BiotechHealthtechSan Francisco, US

Cyrus L. Harmon, Ph.D.(Director)Cyrus Harmon(Executive Officer, Director)inCLCyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)in

Co-investorsAVAvoro Capital AdvisorsBABain Capital Life SciencesLILightspeed Venture PartnersRARA CapitalBIBiotechnology Value FundLOLogos+1 more

Omeros is a publicly traded biotech company developing a diverse pipeline of first-in-class small-molecule and antibody therapeutics targeting unmet medical needs across multiple therapeutic areas and indications.

BiotechHealthtechMedical DevicesSeattle, US

Co-investorsSPSPRINGROCK VENTURES

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

MMMathai Mammen(CEO, President and Chairman)in

Co-investorsARARCH Venture PartnersCACatalio Capital Management, LPFRFrazier Life SciencesGEGeneral CatalystNENextech InvestRARA Capital+7 more

Quince Therapeutics is a biotechnology company developing the AIDE technology platform, a drug/device combination that encapsulates medications into a patient's own red blood cells to improve drug delivery for rare diseases.

BiotechSouth San Francisco, US

Stephen Dominy(Director)Casey Lynch(Executive Officer, Director)Charles Ryan(Executive Officer)inBrendan Hannah(Executive Officer)DTDirk Thye(Executive Officer, Director)inKristen Gafric(Executive Officer)

Co-investorsSOSofinnova PartnersTATakeda Ventures

Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.

AI & Machine LearningBiotechDeep TechCambridge, US

Donald A. Bergstrom(Executive Officer)inSKSanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)

Co-investorsCOCommonweal VenturesECEcoR1 CapitalNENextech InvestSOSoftBank Vision FundCUCurie.BioGEGeneral Catalyst+1 more

Replimune is a biotech company developing oncolytic immunotherapies designed to activate immune responses against difficult-to-treat cancers.

BiotechHealthtechMedical Devices

Robert Coffin(Founder and Chief Scientist)Sushil Patel(Chief Executive Officer)Emily Hill(Chief Financial Officer)Konstantinos Xynos(Chief Medical Officer)

Co-investorsATAtlas VentureBABain Capital Life SciencesREREDMILE

Revolution Medicines develops drug candidates targeting specific genetic mutations in cancer and other serious diseases, advancing them through clinical trials toward regulatory approval and commercialization.

BiotechRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)

Co-investorsBABain Capital Life SciencesNENextech InvestTHThird Rock Ventures

RxSight develops the Light Adjustable Lens (LAL), an FDA-approved intraocular lens that surgeons can adjust after cataract surgery to fine-tune a patient's prescription once the eye has healed.

HealthtechMedical DevicesPasadena, US

Robert H. Grubbs(Director)Daniel M. Schwartz(Director)D. Verne Sharma(Executive Officer, Director)Richard Drinkward(Executive Officer)inRKRon Kurtz(President, Chief Executive Officer & Director)MWMark Wilterding(Chief Financial Officer)in

Co-investorsFLFlying L PartnersH.H.I.G. CapitalH.H.I.G. HealthBridge PartnersLOLongitude CapitalRARA CapitalVIVisionary Ventures+2 more

SCYNEXIS develops fungerp-based antifungal therapies, including SCY-247, for treating and preventing severe, progressive, and often fatal fungal diseases and antimicrobial-resistant infections.

BiotechDurham, US

Yves J. Ribeill(Executive Officer, Director)inCharles F. Osborne, Jr.(Executive Officer)Brian Schwab(Executive Officer)inDADavid Angulo(Chief Executive Officer, President and Director)in

BoardLaurent Arthaud(Director)Mounia Chaoui(Director)

Co-investorsDEDecheng CapitalDEDeerfield Management CompanyRARA Capital

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

DZDaphne Zohar(Founder, CEO and Board Member)inMCMichael Chen(Executive Officer)inLGLana Gladstein(Executive Officer)inALAntony Loebel(Executive Officer)inEGEric Green(Executive Officer)in

BoardJIJames I. Healy(Director)

Co-investorsARARCH Venture PartnersHAHAWKTAILPUPureTech HealthSOSofinnova VenturesTHThird Rock Ventures

Silence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.

BiotechLondon

Craig Tooman(Executive Officer)inGiles Campion(Executive Officer)Mark Rothera(Executive Officer, Director)inBarbara Ruskin(Executive Officer)

BoardJames Ede-Golightly(Director)Alistair Gray(Director)

Co-investorsMCMC Healthcare VenturesNENextech InvestVIVivo Capital

Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy.

BiotechHealthtechCharlestown, US

IGIlan Ganot(Co-Founder and Director)inStephen DiPalma(Executive Officer)CMCarl Morris(Executive Officer)inAlexander Cumbo(President, Chief Executive Officer and Director)MFMartin Freed(Director)inPaul Herizch(Executive Officer)

Co-investorsBABain Capital Life SciencesRARA Capital

BiotechSouth San Francisco, US

Grant E. Pickering(Chief Executive Officer)Ashish Khanna(Executive Officer)Jeff Fairman(Executive Officer)

BoardTracy Saxton(Director)William Newell(Director)KVKurt von Emster(Director)in

Co-investorsABAbingworthCTCTI Life Sciences Fund L.P.FRFrazier Life SciencesJAJanus Henderson InvestorsLOLongitude CapitalMEMedicxi+4 more

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.

BiotechWaltham, US

John Pallies(Executive Officer)inAMArlene Morris(Executive Officer, Director)inMAMichael A. Metzger(Chief Executive Officer)inKAKeith A. Goldan(Chief Financial Officer)in

BoardDPDennis Podlesak(Director)inIvor Royston(Director)

Co-investorsPAPappas CapitalSOSofinnova VenturesVEvenBio PartnersBLBlackRockDODomain AssociatesMPMPM BioImpact

Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.

BiotechBoston, US

AHAlan Huang(Executive Officer)inACAdam Crystal(Executive Officer)inDBDaniella Beckman(Executive Officer)inDouglas Barry(Executive Officer)Aaron Davis(Director)

BoardBWBarbara Weber(Executive Officer, Director)in

Co-investorsNENextech InvestNSNSG VenturesTHThird Rock Ventures

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.

BiotechHealthtech

GPGrant Pickering(Founder)inGEGrant E. Pickering(Chief Executive Officer and Director)in

Co-investorsBIBioRock VenturesCTCTI Life Sciences Fund L.P.FRFrazier Life SciencesLOLongitude CapitalRARA CapitalJAJanus Henderson Investors+2 more

Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.

BiotechMedical DevicesNeedham, US

RWRobert WeinbergRICHARD ALDRICH(Director)ACAMY C. CAVERS(Executive Officer)inCCCATHY CAREW(Executive Officer)inJPJONATHAN PACHTER(Executive Officer)inRGROB GAGNON(Executive Officer)in

Co-investorsBEBessemer Venture PartnersCACardinal PartnersLILightstone VenturesLOLongwood FundOBOberland CapitalOROrbiMed

Wave Life Sciences develops RNA-targeting therapeutics using RNA-editing modalities and chemistry to treat rare and common diseases, with a clinical pipeline addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity.

BiotechHealthtechLongevitySingapore

TWTakeshi Wada(Director)inGLGregory L. Verdine(Director)PBPaul B. Bolno, M.D.(Executive Officer, Director)in

BoardPKPeter Kolchinsky(Director)inKen Takanashi(Director)Masaharu Tanaka(Director)

Co-investorsRARA Capital

Xenon is a neuroscience-focused biopharmaceutical company that discovers and develops ion channel modulators as therapeutics for neurological and psychiatric disorders.

BiotechHealthtech

IMIan Mortimer(President and Chief Executive Officer)inDCDarren Cline(Chief Commercial Officer)inADAndrea DiFabio(Chief Legal Officer and Corporate Secretary)inJEJames Empfield(Executive Vice President, Drug Discovery)inTKTucker Kelly(Chief Financial Officer)inCKChris Kenney(Chief Medical Officer)in

Co-investorsAVAvoro Capital AdvisorsNENew Enterprise Associates (NEA)

Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.

AI & Machine LearningBiotechWatertown, US

Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRGRobert Gagnon(Executive Officer)HWHeather Wasserman(Executive Officer)inMPMatthew Patterson(Director)inSBScott Biller(Director)in

Board seatMRMichael Rome· per SEC Form D

Co-investorsATAtlas VentureTHThe Column GroupARARCH Venture PartnersDEDecheng Capital

bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications.

BiotechDeep TechHealthtechMedical Devices

DMDr Mark Kotter(Founder)POPrzemek Obloj(CEO)inEPEmma Pepperellin

Co-investorsBLBlueYard CapitalARARCH Venture PartnersDYDynamk CapitalGOGood AI CapitalHAHAWKTAILMEMetaplanet+2 more

Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US

CTCraig Thompson(Chief Executive Officer)inSVSagar Vaidya(Chief Medical Officer)inCarrie Ann Cook(Chief Business Officer)MCMark Carlton(Chief Scientific Officer)inOVOttavio V. Vitolo(Chief Medical Officer)in

Co-investorsGVGV (Google Ventures)DEDementia Discovery FundSVSV Life SciencesDEDementia DiscoveryLILightstone VenturesSVSV Health Investors+2 more

HealthVerity operates a healthcare and consumer data ecosystem that enables HIPAA-compliant synchronization and exchange of real-world data across pharma, payers, and government agencies.

Data & InfrastructureEnterprise SoftwareHealthtechPhiladelphia, US

AKAndrew Kress(Co-Founder and CEO)inAGAndrew Goldberg(Co-Founder and COO)

BoardMGMichael Greeley(Director)inRachel Winokur(Director)

Co-investorsFLFlare Capital PartnersGRGreycroftNENew Enterprise Associates (NEA)

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsLOLongwood FundNONorwest Venture PartnersRIRiverVest Venture PartnersYSYsios CapitalABabrdn plcEIEight Roads Ventures+4 more

Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays.

BiotechHardwareHealthtech

Co-investorsMEMedical Excellence CapitalDEDeerfield Management Company

Spear Bio develops high-sensitivity immunoassays based on its SPEAR (Successive Proximity Extension Amplification Reaction) technology, which originated from research at the Wyss Institute.

BiotechHealthtechMedical Devices

Feng Xuan(Chief Executive Officer & Co-founder)Peng Yin(Director & Co-Founder)

Co-investorsMAMaverick VenturesYOYonghua Capital

BiotechSan Diego, US

Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)

BoardBret Zbar(Director)Carl Gordon(Director)

Board seatMRMichael Rome· per SEC Form D

Co-investorsNENextech InvestJAJanus Henderson InvestorsRARA CapitalVEVenrock Healthcare Capital PartnersVIViking Global Investors

Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.

BiotechHealthtechSan Francisco, US

ULUri Lopatin(Founder/CEO)inUri A. Loptain(Executive Officer, Director)HHHeidi Henson(Executive Officer)inElizabeth Lacy(Executive Officer)Lee Arnold(Executive Officer)

BoardJ. Jay Lobell(Director)

Board seatJames B. Tananbaum· per SEC Form D

Co-investorsY Y CombinatorKHKhosla Ventures

Riskgaming creates immersive strategy simulation games where high-level decision-makers assume roles and navigate complex scenarios involving technology, business, and geopolitical challenges to explore alternative outcomes and inform real-world decisions.

BiotechHayward, US

Kegan Schouwenburg(Executive Officer, Director)RMRoger M. Perlmutter(Executive Officer, Director)in

BoardJWJoshua Wolfe(Director)inDror Berman(Director)Leon Chen(Director)

Board seatJames Tananbaum· per SEC Form D

Co-investorsBABain Capital Life SciencesCICisco InvestmentsLULux CapitalDIDimension Capital

Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable.

BiotechPhiladelphia, US

David Brand(Executive Officer, Director)inGregory Lumpkin(Executive Officer)

BoardRichard Kollender(Director)Martin Edwards(Director)EBEric Bednarski(Director)Derek Ferguson(Director)

Board seatJames Tananbaum· per SEC Form D

Co-investorsMVMVM Life Science PartnersOXOxford Finance LLCQUQuaker BioVentures

BiotechCambridge, US

William C. Shakespeare(Director)in

BoardIDIain Dukes(Executive Officer, Director)inCGCarl Gordon(Director)in

Board seatMRMichael Rome· per SEC Form D

Co-investorsLOLongitude CapitalNENextech InvestNENexTech VenturesOROrbiMedPOPontifax Venture CapitalRORock Springs Capital+1 more

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Co-investorsBABain Capital Life SciencesNENew Enterprise Associates (NEA)RARA CapitalSASamsara BioCapitalSASanofi VenturesMAMass General Brigham Ventures+8 more

A pharmaceutical company that develops medicines and vaccines for patients globally.

BiotechHealthtechMedical DevicesCambridge, US

WYLIE W. VALE(Director)JKJOHN KNOPF(Executive Officer, Director)STEVEN ERTEL(Executive Officer)RSROBERT STEININGER(Executive Officer)inKEVIN F. MCLAUGHLIN(Executive Officer)inMLMATTHEW L. SHERMAN(Executive Officer)

Co-investorsBEBessemer Venture PartnersLILightstone VenturesLOLowercarbon CapitalSOSofinnova VenturesVEVenrockCOCollaborative Fund

Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.

BiotechHealthtechMedical DevicesBedminster, US

CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BLBRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)DEDavid Endicott(CEO of Alcon)in

Co-investorsALAlta PartnersAVAvoro Capital AdvisorsOUOUP (Osage University Partners)SOSofinnova Ventures

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.

BiotechMedical DevicesCambridge, US

Richard Malley(Director)inKamran Tavangar(Executive Officer)SBSteven Brugger(Executive Officer, Director)in

BoardRobert More(Director)Frances Heller(Director)George Siber(Director)

Co-investorsBABain Capital Life SciencesECEcoR1 CapitalBABain CapitalRORock Springs CapitalT.T. Rowe Price

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsATAtlas VentureFRFrazier Life SciencesSCScion Life SciencesTHThe Innovation SpaceVEvenBio PartnersVEVersant Ventures

Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.

BiotechDeep TechHealthtechLongevity

NRNils Regge(Co-Founder & General Partner)in

Co-investorsBLBLN CapitalCOCoastCapFJFJ LabsKFKfW CapitalTRTruVenturo GmbHCTCTI Life Sciences Fund L.P.+3 more

Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.

Biotech

Juan Jaen(Founder)in

Co-investorsAIAisling CapitalDEDecheng CapitalDRDroia VenturesECEcoR1 CapitalSLSLVCSOSofinnova Ventures+2 more

Ardelyx is a biopharmaceutical company that develops first-in-class medicines for patients with unmet medical needs.

BiotechFremont, US

Mark Kaufmann(Executive Officer)EGElizabeth Grammer(Executive Officer)inDRDavid Rosenbaum(Executive Officer)inJeremy Caldwell(Executive Officer)MRMike Raab(Executive Officer, Director)in

BoardDavid Mott(Director)

Co-investorsHEHEALTHCARE ROYALTY PARTNERSNENew Enterprise Associates (NEA)

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.

BiotechHealthtechMedical DevicesNewtown Square, US

Z(Zhengbin (Bing) Yao(Executive Officer, Director)inBRBrent Rice(Chief Commercial Officer)in

BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)

Co-investorsCACatalio Capital Management, LPGEGeneral CatalystHOHongShan Capital GroupLALAVLILilly Asia VenturesOROrbiMed+2 more

Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.

BiotechHealthtechMedical DevicesDenmark, DK

JMJan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)MAMartin Auster(Executive Officer)in

Co-investorsVIVivo CapitalAIAisling CapitalAVAvoro Capital AdvisorsRARA CapitalSOSofinnova Ventures

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

Biotech

Athena Countouriotis(Co-Founder, Chief Executive Officer)

Co-investorsDEDelos CapitalININCE CapitalLOLongwood FundNENew Enterprise Associates (NEA)OROrbiMedQUQuan Capital+3 more

Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.

BiotechHealthtechCambridge, US

Nick Lydon(Director)CSChristoph S. Lengauer(Executive Officer)inChristine Bellon(Executive Officer)inKyle Kuvalanka(Executive Officer)in

BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)

Co-investorsF-F-Prime CapitalNENextech InvestRARA Capital

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

KSKen Song(Chairman, President and CEO)inKSKenneth Song, M.D.(Executive Officer, Director)AKArvind Kush(Executive Officer)TLTimothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsOROrbiMedSASamsara BioCapitalTCTCG CrossoverTHThird Rock VenturesVEvenBio PartnersVIVida Ventures

CareGuide operates online marketplaces that connect people seeking care services with qualified caregivers across various verticals including pet care, home services, and childcare.

ConsumerDigital HealthHealthtechHR TechMarketplacesSaaSToronto, US

JGJohn GreeninADAli Dinani(Chief Executive Officer)inKSKen Scott(Chief Financial Officer)inEHEmir Hasanbegovic(Chief Technology Officer)in

BoardJesse Rasch

Co-investors50500 GlobalGAGarage CapitalINInovia CapitalSTStructure CapitalPLPlaza Ventures

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

BiotechHealthtech

Co-investorsADAdvent Life SciencesECEcoR1 CapitalMEMedicxiOBOberland CapitalSCScion Life SciencesVIVida Ventures+1 more

Chimagen Biosciences is a Shanghai-based clinical-stage biotech developing multi-specific antibody therapeutics, including T-cell and NK-cell engagers, for cancer and autoimmune diseases.

Color Health operates a nationwide virtual cancer clinic delivering oncologist-led care, screening, and treatment management for employer, union, health plan, and public sector populations.

AI & Machine LearningDigital HealthHealthtechSan Francisco, US

OLOthman Laraki(CEO)in

Co-investors8V8VCCOComcast VenturesCRCRV (Charles River Ventures)DRDria VenturesHOHomebrewKIKindred Ventures+9 more

ConnectiveRx provides hub services, patient support, and patient affordability programs that help pharmaceutical manufacturers, healthcare providers, and patients access and stay on prescribed therapies.

Digital HealthHealthtechSaaS

Co-investorsGEGenstar

Corvus Pharmaceuticals is a biopharmaceutical company developing immunology-focused medicines that target cellular components of the immune system, with therapeutic focus on immune diseases and cancer.

BiotechHealthtechBurlingame, US

RARichard A. Miller(President & CEO, Co-Founder)inLeiv Lea(Executive Officer)in

BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)PTPeter Thompson(Co-Founder)inTerry G. Gould(Director)

Co-investorsAVAvoro Capital AdvisorsOROrbiMed

Crossover Health operates an integrated primary care delivery model centered on member experience, using proprietary technology and care structures to expand healthcare access and accountability.

Digital HealthHealthtech

Ryan Smith

Co-investorsNONorwest Venture Partners

CSClint Sever(Founder)in

Co-investorsACACME CapitalDADarwin CapitalDEDecheng CapitalDEDentsu VenturesPRPrime PartnersCACAVU Consumer Partners+1 more

Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California that discovers, develops, and delivers medicines across virology, oncology, and inflammation.

BiotechHealthtechMedical DevicesNewark, US

Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)

BoardCarl Goldfischer, M.D.(Director)KVKurt von Emster(Director)in

Co-investorsAVAvoro Capital AdvisorsBABay City CapitalVAVantagePoint Capital Partners

DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US

VVVictor Velculescu(Founder and Board Director)inPBPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)inSTSusan Tousi(Chief Executive Officer)in

Co-investorsAVAV8 VenturesILIllumina VenturesINInitiate Venture PartnersMEMenlo VenturesOPOpen Field CapitalOROrbiMed+5 more

HealthtechMenlo Park, US

Thomas G. Wiggans(Executive Officer, Director)inEugene A. Bauer(Executive Officer, Director)Andrew Guggenhime(Executive Officer)Luis Pena(Executive Officer)Christopher Griffith(Executive Officer)

BoardFCFred Craves(Director)in

Co-investorsAIAisling CapitalBABay City CapitalCACanaan PartnersNENew Enterprise Associates (NEA)FIFidelity InvestmentsQIQiming Healthcare+1 more

DNAnexus operates a cloud platform for managing, analyzing, and collaborating on multiomic and clinical data, supporting bioinformatics workflows, AI/ML analytics, and cohort analysis.

AI & Machine LearningBiotechCloud ComputingData & InfrastructureMountain View, US

ASAndreas Sundquist(Executive Officer, Director)inRDRichard Daly(Executive Officer, Director)inGeorge Asimenos, PhD(Chief Product Officer)in

BoardMGMichael Goldberg(Director)Geoff Duyk(Director)KYKrishna Yeshwant(Director)in

Co-investorsCLClaremont Creek VenturesGVGV (Google Ventures)K9K9 VenturesUNUncork CapitalWIWireframe Ventures

Element Materials Technology provides materials testing, product qualification, and assurance services for customers in aerospace, space, defense, and energy sectors.

Advanced ManufacturingDeep TechDefense TechEnterprise SoftwareMedical DevicesNew Materials

Rick Sluiters(CEO of Element Aero, Space & Defense)

Co-investors3I3i GroupMEMetaplanetPRProtocol LabsT.T. Rowe PriceVEVenrock

Element is an NFT marketplace on Ethereum where users can create, swap, and trade NFT collections, with real-time floor price and volume data tracking.

Crypto & Web3Marketplaces

Co-investorsBIBitDAOMAMantle NetworkMEMetaplanetPRProtocol LabsT.T. Rowe PriceVEVenrock

Element Biosciences develops biological analysis platforms and DNA sequencing tools for scientists and research institutions.

BiotechDeep TechHardwareMedical Devices

Co-investorsDRDraper AssociatesFUFusionRARA CapitalTSTSVCVEVenrock

Everlywell offers at-home lab testing kits and virtual healthcare services across multiple wellness categories including daily health screening, digestive analysis, sexual health testing, and hormone monitoring.

ConsumerDigital HealthHealthtechWellness & Fitness

JCJulia Cheek(Founder & CEO)in

Co-investorsANAnsa CapitalBRBreyer CapitalCECerity Partners VenturesHAHalogen Ventures Management Company LlcLULux CapitalNENext Coast Ventures+10 more

Fabric Genomics provides an AI-based platform for next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesOakland, US

MRMartin Reese(Co-Founder, President, and CEO)inMartin Reese, Ph.D.(Co-Founder, President, and CEO)EFErwin Frise(Vice President of Technology and Data Science)in

Co-investorsARArtis VenturesMIMighty CapitalCACasdin Capital

FOLX is a digital healthcare platform designed for LGBTQIA+ adults, providing inclusive and affirming medical care.

Digital HealthHealthtechBoston, US

ABA.G. Breitenstein(Founder)inLBLena Ballantine(Executive Officer)inLMLiana M Guzman Weis(Executive Officer, Director)

BoardLCLynne Chou O'Keefe(Director)inMorgan Cheatham(Director)inLSLee Shapiro(Director)in

Co-investors7W7wire VenturesBEBessemer Venture PartnersCOCorewell Health VenturesDEDefine VenturesHAHabitat PartnersSESeae Ventures+2 more

BiotechCambridge, US

Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)MAMark Angelino(Executive Officer)

BoardJRJason Rhodes(Director)inCSCatherine Stehman-Breen(Director)Anthony Quinn(Director)

Co-investorsATAtlas VentureF-F-Prime CapitalINInvus

Genomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers.

AI & Machine LearningBiotechDigital HealthHealthtechOxford, GB

PDPeter Donnellyin

Co-investorsF-F-Prime Capital

Data & InfrastructureDigital HealthHealthtechNew York, US

Sebastian G. Schneeweiss(Director)WGWilliam Geary(Director)inJeremy Rassen(Executive Officer, Director)

Co-investorsB B Capital GroupB4B4 CapitalBLBlue Lion GlobalFLFlare Capital PartnersLGLG Technology VenturesMCMcKesson Ventures+6 more

US direct-to-consumer telehealth company selling prescription and OTC treatments online by subscription; NYSE-listed as HIMS.

JAJack Abraham(Co-founder)in

Co-investors7G7GC & Co8V8VCA-A-Rod CorpATAtomicBRBrentwood AssociatesCACAVU Consumer Partners+17 more

Identifeye provides a fundus imaging platform combining a portable camera device and cloud-based portal software for retinal screening in point-of-care settings.

AI & Machine LearningDigital HealthHealthtechMedical Devices

BiotechBoulder, US

Michael Graige(Executive Officer)Ron McGrath(Executive Officer)SKSri Kosaraju(Executive Officer, Director)Dianna L. DeVore(Executive Officer)

BoardRWRoger Wyse(Director)inBRBryan Roberts(Director)in

Co-investorsIGiGlobe PartnersKOKorysOAOak HC/FTOMOMX VenturesPAPaladin Capital GroupSPSpruce Capital Partners+3 more

insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.

AI & Machine LearningBiotechSouth San Francisco, US

DKDaphne Koller(CEO & Founder)inDVDuane Valz(General Counsel)inMRMary Rozenman(Chief Financial Officer)in

BoardRNRobert Nelsen(Director)VPVijay Pande(Director)in

Co-investorsANAndreessen HorowitzARARCH Venture PartnersGVGV (Google Ventures)HOHOF CapitalSOSoftBank Vision FundALAlexandria+7 more

Irvine, US

DVDavid Van Meter(Executive Officer, Director)

BoardTara Butler(Director)Douglas Roeder(Director)ABAli Behbahani(Director)inRandy Alexander(Director)Thong Yuen Poon(Director)

Co-investorsASAscension VenturesMEMemorialCare Innovation FundNENew Enterprise Associates (NEA)RARA Capital

Jade Biosciences develops therapeutic antibodies targeting autoimmune diseases, with a lead candidate in clinical development for immunoglobulin A nephropathy, a chronic kidney disease.

BiotechHealthtech

Co-investorsFRFrazier Life Sciences

Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.

BiotechHealthtechNewton, US

SPStuart Poulton(Executive Officer)inMichael Mano(Executive Officer)inRRReshma Rangwala(Executive Officer)inRPRichard Paulson(Executive Officer, Director)inStephen Mitchener(Executive Officer)inMichael Mason(Executive Officer)in

Co-investorsAVAvoro Capital AdvisorsHEHEALTHCARE ROYALTY PARTNERSRARA Capital

Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.

BiotechMedical Devices

Co-investorsNENextech InvestALAlexandriaLILilly Asia VenturesLOLongwood Fund

Kira Pharmaceuticals is a biotech company developing therapies targeting complement biology to treat complement-mediated diseases.

BiotechHealthtechCambridge, US

WSWenru Song(Founder)in

Co-investorsQUQuan CapitalVIVivo CapitalIKIkarian Capital

Kriya provides working capital loans and business finance products to UK and European businesses, helping them manage cash flow, fund wholesale orders, and scale their buyer base.

FintechSaaS

ASAnil Stocker(Founder)in

Co-investorsMOMouro CapitalNONorthzoneBLBluebird VenturesJDJDRF T1D FundNANarya CapitalPAPatient Square Capital+1 more

Kriya Therapeutics is a biopharmaceutical company that develops and manufactures one-time gene therapies aimed at treating prevalent chronic diseases.

BiotechHealthtechMorrisville, US

SRShankar Ramaswamy(Co-Founder, Chairman & CEO)inRJRoger Jeffs(Co-Founder & Vice Chairman)inFWFraser Wright(Scientific Co-Founder & Chief Gene Therapy Officer)inSRShankar Ramaswamy, M.D.(Founder)inMSMichele Stone(Chief Scientific Officer)inKEKatherine Eade(Chief Legal Officer)

Co-investorsPAPatient Square CapitalPRPremji InvestAMAmplo VenturesBLBluebird VenturesJDJDRF T1D FundNANarya Capital+2 more

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.

BiotechHealthtechMedical DevicesThousand Oaks, US

NFNima Farzan(Executive Officer, Director)TLTim Lugo(Executive Officer)

BoardBSBeth Seidenberg(Director)inJTJim Tananbaum(Director)inDPDeborah Palestrant(Director)inKevin Raidy(Director)

Co-investorsACAccess BiotechnologyKEKern Capital, LLCSASanofi Ventures5A5AM VenturesWEWestlake Village BioPartners

Lucira Health manufactures portable diagnostic devices that connect to smartphones to test bodily fluids for infectious diseases, enabling rapid results outside of clinical settings.

BiotechHealthtechMedical DevicesEmeryville, US

DMDebkishore Mitra(Founder)inJohn R. Waldeisen(Director)

BoardErik T. Engelson(Executive Officer, Director)Justin Butler(Director)Tuff Yen(Director)Steve Tablak(Director)

Co-investors1111.2 CapitalSHShangBay Capital LLCY Y CombinatorOSOS Fund

Lyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology.

BiotechDeep TechHealthtechMedical DevicesBothell, US

Stan Riddell(Executive Officer)Richard Klausner(Executive Officer, Director, Promoter)Stephen Hill(Executive Officer)inHTHeather Turner(Executive Officer)inRichard Goold(Executive Officer)inMargo Roberts(Executive Officer)

Co-investorsARARCH Venture PartnersVEvenBio Partners8V8VCAXAxial VC

Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.

BiotechDeep TechMedical DevicesBrisbane, US

JDJennifer Doudna(Founder)inTMTrevor Martin(Co-founder, Chief Executive Officer)inJCJanice Chen(Co-founder, Chief Scientific Officer & President, Research)inLHLucas Harrington(Co-founder)inATAshley Tehranchi(Executive Officer, Director)in

BoardUrshit Parikh(Director)

Co-investors8V8VCBEBerkeley FrontierCACALIFORNIA INNOVATIONDEDecheng CapitalMAMayfield FundMIMission Bay Capital+9 more

Virtual women's health clinic offering insurance-covered perimenopause, menopause and midlife care in all 50 U.S. states.

JSJoanna Strober(Founder)in

Co-investors2525MadisonFEFelicis VenturesICIcon VenturesSTSteelSky VenturesADAdvance Venture PartnersGIGingerbread Capital+4 more

Mirvie develops an RNA-based platform for early detection of pregnancy complications, enabling proactive intervention before complications become critical.

BiotechFemTechHealthtechSouth San Francisco, US

MJManeesh Jain(Executive Officer, Director, Promoter)inSQStephen Quake(Director)

BoardLisa Iverson(Director)UPUrsheet Parikh(Director)inMCMin Cui(Director)inSKSamir Kaul(Director)in

Co-investorsDEDecheng CapitalMAMayfield FundPOPortfoliaBLBlackRockGEGeneral CatalystGVGV (Google Ventures)+1 more

MyOme provides genomic insights and clinical genetic screening reports to help individuals and healthcare providers assess risks for hereditary conditions and make informed health decisions.

BiotechDigital HealthHealthtechMedical Devices

AKAkash Kumar(Chief Medical and Scientific Officer / Co-Founder)inKate Im(Senior Vice President of Research / Co-Founder)in

Co-investorsHOHOF CapitalSASamsung Next

Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology.

AI & Machine LearningBiotechHealthtech

ADArvin Dar(Co-founder & Board Observer)inKevan Shokat(Scientific Co-founder)KHKlaus Hoeflich(Co-founder & former Chief Scientific Officer)inDMDarrin Miles(Chief Executive Officer)inPKPhilip Komarnitsky(Chief Medical Officer)inTanja Weber(Chief Business Officer)in

Co-investorsVEVersant VenturesSISixty Degree CapitalCOCowen Healthcare InvestmentsGOGoldman SachsSESection 32

Novavax develops protein-based nanoparticle vaccines paired with its Matrix-M adjuvant to produce broad, long-lasting immune responses.

BiotechHealthtech

Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US

ATArthur T. Sands(Executive Officer, Director)inGMGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)

BoardDavid Goeddel(Director)inMark Goldsmith(Director)

Co-investorsBABain Capital Life SciencesECEcoR1 CapitalSOSofinnova VenturesTHThe Column Group

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.

BiotechMedical DevicesCambridge, US

GDGary D Glick(Executive Officer, Director)in

BoardJCJill Carroll(Director)inCGCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)in

Co-investorsACActivant CapitalBABalderton CapitalCACatalio Capital Management, LPGLGlobal BioAccess FundGRGreatPoint VenturesJEJeito Capital+6 more

Optinose is a specialty pharmaceutical company that develops and markets products for patients with conditions treated by ear, nose, and throat (ENT) and allergy specialists.

BiotechHealthtechMedical DevicesYardley, US

Per Djupesland(Executive Officer, Director)inMichele Janis(Executive Officer)Peter Miller(Executive Officer, Director)inTerrence Terifay(Executive Officer)Ramy Mahmoud(Executive Officer)in

BoardKlaas De Boer(Director)

Co-investorsMVMVM Life Science Partners

Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.

BiotechDeep TechHealthtechMedical DevicesLondon, GB

Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)FEFrank E. Thomas(Executive Officer)inSteven M. Altschuler(Director)John Curnutte(Director)

BoardBGBobby Gaspar(Scientific Founder)in

Co-investorsALAlbionVCF-F-Prime CapitalUCUCL Technology FundAGAgent CapitalBABaillie GiffordORORI Capital+1 more

Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.

BiotechHealthtech

Co-investorsBABain Capital Life SciencesKUKurma PartnersVEvenBio Partners

Pinnacle Medicines develops oral peptide-based therapies designed to deliver antibody-like efficacy in pill form for patients with chronic diseases.

BiotechDigital HealthDoylestown, US

CSChengzao Sun(Founder)inSandeep Somani(Founder)in

Co-investorsQUQuan CapitalRARA CapitalLALAVOROrbiMed

Puma Biotechnology is a biopharmaceutical company focused on acquiring, developing, and commercializing therapeutics for cancer treatment.

BiotechHealthtech

Quantum-Si develops next-generation protein sequencing technology that enables single amino acid detection by combining biology, chemistry, artificial intelligence, and semiconductor technology.

BiotechDeep TechHardwareMedical Devices

JHJeff Hawkins(CEO)inJKJeff Keyes(Chief Financial Officer)inCLChristian LaPointe(General Counsel)inTRTodd Rearick(Chief Technology Officer)inLindsay Thompson(Chief Human Resources Officer)in

Co-investorsHIHighCape CapitalYUYuanBio Venture Capital

RayThera develops small molecule therapies targeting unmet needs in immunology.

BiotechHealthtech

Co-investorsOROrbiMed

Redesign Health is a venture capital and applied technology platform that builds and invests in next-generation healthcare companies using AI-native strategies.

AI & Machine LearningDigital HealthHealthtech

Co-investorsCVCVS Health VenturesDEDeclaration PartnersFOForerunner VenturesMAMantis CapitalRIRiverPark VenturesSASamsung Next

Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Keith Gottesdiener(Executive Officer, Director)inBHBart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDMDavid Meeker(President and Chief Executive Officer)in

BoardETEdward T. Mathers(Director)inJSJonathan Silverstein(Director)inNENeil Exter(Director)in

Co-investorsHEHEALTHCARE ROYALTY PARTNERSNENew Enterprise Associates (NEA)PFPfizer Venture InvestmentsOROrbiMedTHThird Rock Ventures

Sangamo Therapeutics develops gene-editing therapeutics using zinc finger and modular integrase platforms to treat genetic diseases including hemophilia, Fabry disease, and neuropathy.

BiotechDeep TechHealthtechMedical DevicesUnknown based on the provided page content, US

SMSandy Macrae(Chief Executive Officer)in

Co-investorsCACalifornia Technology VenturesFOFoothill VenturesRIRidgeback Capital

Signant Health provides software platforms and clinical trial solutions for life sciences companies to manage patient-reported outcomes, evidence generation, and digital endpoints in drug development programs across multiple therapeutic areas.

BiotechDigital HealthEnterprise SoftwareHealthtechMedical DevicesSaaSBlue Bell, US

Roger Smith(Chief Executive Officer)in

Co-investorsGEGenstar CapitalGEGenstar

Good Lab is a brand and design agency serving early-stage, rapid-growth ventures in health, wellness, environmental sciences, and life sciences.

Creator EconomyMarketing Tech

JMJohn Montgomery(Founder)in

Slate Medicines is a clinical-stage biotechnology company.

BiotechMedical DevicesBoston, US

Sara Pacheco(Executive Officer)Neil Buckley(Executive Officer, Director)inGOGregory Oakes(Chief Executive Officer and Board Director)in

BoardTim Lohoff(Director)CXCindy Xiong(Director)inALAndrew Levin(Director)

Co-investorsRARA Capital

SomaLogic develops proteomics tools that help researchers measure protein function and study human biology across a range of scientific applications.

BiotechDeep TechHealthtechBoulder, US

LGLarry Gold(Director)inLGLarry Gold PhD(Founder)inDaniel Muehl(Executive Officer)BHByron Hewett(Executive Officer, Director)in

BoardCharles Lillis(Director)Youichi Yabuuchi(Director)

Co-investorsKHKhosla VenturesCACasdin CapitalMAMagnetar CapitalREReimagined VenturesSOSoleus CapitalT.T. Rowe Price

Co-investorsF-F-Prime CapitalQIQiming Venture Partners

Tasso develops diagnostic testing devices and platforms for home use, enabling patients to perform health monitoring and inform clinical decisions outside traditional healthcare settings.

Digital HealthHealthtechMedical DevicesSeattle, US

BCBen Casavant(Co-Founder and Chief Executive Officer)inEBErwin Berthier(Co-Founder and Chief Technology Officer)inALAlan Levy(Director)

BoardElizabeth Hambrecht(Director)PCPaul Conley(Director)in

Co-investorsJ2J2 VenturesOMOMX VenturesRARA CapitalTETechstarsVEVenture Capital Investment ManagementVEVertical Venture Partners

Theseus builds robotic situational awareness software using visual positioning for drones that operate in GPS-denied environments.

Advanced ManufacturingAI & Machine LearningDefense TechHardwareRoboticsSan Francisco, US

ILIan Laffey(Founder)inSLSacha Lévy(Founder)in

Co-investorsY Y CombinatorANAntlerFIFirst Round CapitalLOLongitude CapitalLULux CapitalNENexTech Ventures+4 more

Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.

BiotechMedical DevicesLower Gwynedd, US

Joseph Erhardt(Executive Officer)inPeter Lebowitz(Executive Officer, Director)

BoardAGArjun Goyal(Director)inOtello Stampacchia(Director)inFDFrancesco Draetta(Director)in

Co-investorsANAndreessen HorowitzVIVida VenturesABabrdn plcBIBiotechnology Value FundHIHillhouse InvestmentOMOmega Funds+1 more

Thyme has partnered with Altruist to create Hazel, an AI product for wealth management professionals.

AI & Machine LearningEnterprise SoftwareFintechSan Francisco, US

DLDaniel Lantz(Founder)inFSFernando San Martin(Founder)in

Co-investorsY Y CombinatorALAlleyCorpCOConcord Health PartnersCVCVS Health VenturesFRFrist Cressey VenturesHUHumana+1 more